Founder, Chairman And Ceo
CurrentBiosion, Inc. is a global clinical-stage biotechnology company discovering and developing innovative therapeutics for oncology and immunological diseases. Leveraging our proprietary H³ (High-throughput, High-content, High-efficiency) antibody platform, SynTracer™ HT-endocytosis platform, and Flexibody™ bifunctional antibody platform, Biosion is committed to discovering and developing innovative biologics for patients with unmet medical needs. The company is building a proprietary therapeutic pipeline through its innovative internal discovery efforts and through co-development programs in collaboration with biotech and pharmaceutical companies. For more information, visit www.biosion.com.